Monitoring of biochemical changes in the blood of patients with retinoblastoma before and after treatment
Z.S. ISLAMOV, R.Kh. USMANOV, M.S. GILDIEVA, B.Yu. YUSUPOV, A.A. ABDUVALIEV, Sh. MUSAEVA
Republican Cancer Research Center of the Republic of Uzbekistan, 383 Farabi Str., Tashkent, Republic of Uzbekistan, 100174
Islamov Z.S. ― Cand. Med. Sc., Head of the Ocular Oncology Department, tel. (+998 71) 246-98-86, e-mail: [email protected]
Usmanov R.Kh. ― resident doctor of the Ocular Oncology Department, tel. (+998 71) 246-98-86, e-mail: [email protected]
Gildieva M.S. ― D. Biol. Sc., Head of the Laboratory of Tumor Biology, tel. (+998 71) 246-98-74, e-mail: [email protected]
Yusupov B.Yu. ― D. Med. Sc., scientific consultant of the Department of Head and Neck Tumors, tel. (+998 71) 246-24-15
Abduvaliev A.A. ― Cand. Med. Sc., Senior Researcher of the Laboratory of Tumor Biology, tel. (+998 71) 246-98-74, е-mail: [email protected]
Musayeva Sh.N. ― Junior Researcher of the Laboratory of Tumor Biology, tel. (+998 71) 246-98-74, е-mail: [email protected]
The aim of the study was to investigate the biochemical changes in the blood of patients with retinoblastoma before and after organ-preserving therapy in combination with antioxidants. The research group included 25 patients with mono- and bilateral retinoblastoma without severe comorbidity. The patients underwent poly-chemotherapy according to scheme with antioxidant: Etoposide 100 mg/m2 (1-3 days), Carboplatine 18.6 mg/kg (1-3 days), antioxidant 1 capsule per day (1-3 days). Development of oncopathology in eyes leads to increasing the level of cholesterol in blood serum, as well as high density lipoproteins and thyroxin concentration
Key words: retinoblastoma, poly-chemotherapy, antioxidants.
REFERENCES
1.Singh S., Ramesh V., Premalatha B., Prashad K.V., Ramadoss K. Alterations in serum lipid profile patterns in oral cancer. J Nat SciBiol Med, 2013, no. 4(2), pp. 374-378
2.Maziere C, et al. Oxidized low density lipoprotein induces the cyclin-dependent kinase inhibitor p21(waf1) and the tumor suppressor Rb. BiochemBiophys Res Commun, 2002, no. 293(5), pp. 1327-32.
3.Hellrung A., Bertsch T., Sieber C.C., Bollheimer L.C., Girlich C. Thyroid dysfunction in elderly patients. Dtsch Med Wochenschr, 2014, no. 139(49), pp. 2498-2500.